Literature DB >> 8763998

Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination.

S J Kent1, S L Hu, L Corey, W R Morton, P D Greenberg.   

Abstract

Vaccines for lentiviruses would ideally induce in the host complete resistance to infection of host cells. However, such sterilizing immunity may be neither readily achievable nor absolutely necessary to provide protection from exposure to the immunodeficiency viruses. To examine the nature of protective immunity to simian immunodeficiency virus (SIV), we studied three macaques that had been immunized with a recombinant vaccinia virus-based SIV subunit vaccine regimen and exhibited protection from a challenge with cell-free SIV (MNE) as determined by viral cultures, serology, and PCR for viral genomes. Peripheral blood mononuclear cells were obtained from the protected macaques and analyzed for CD8+ cytotoxic T-lymphocyte (CTL) responses to SIV proteins. CTL reactive to SIV proteins not included in the subunit vaccine, and thus to which these animals had not been exposed prior to challenge, were detected postchallenge in the vaccine-protected animals and persisted for up to 1 year. These CTL, as reflected by studies of cytolytic lines and derived T-cell clones, were CD8+, did not recognize allogeneic targets, and recognized the SIV proteins in the context of class I major histocompatibility complex molecules. The frequency of precursor CD8+ CTL reactive to SIV proteins was determined by limiting-dilution analysis and demonstrated that the responses elicited following challenge of protected animals to SIV proteins not present in the vaccine were quantitatively similar to those of animals persistently infected with SIV. The presence of these CD8+ CTL responses to SIV proteins present only in the challenge virus suggests that infection of some host cells occurred postchallenge. These results suggest that the development of a low level of SIV infection following exposure of vaccinated hosts to SIV does not preclude protection from lethal SIV disease by vaccine-induced immunity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763998      PMCID: PMC190445     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Inoculation of Macaca fascicularis with simian immunodeficiency virus, SIVmne immunologic, serologic, and pathologic changes.

Authors:  L Kuller; W R Morton; R E Benveniste; C C Tsai; E A Clark; M J Gale; S L Hu; M E Thouless; M G Katze
Journal:  J Med Primatol       Date:  1990       Impact factor: 0.667

2.  Humoral immunity and clinical reinfections following varicella vaccine in healthy children.

Authors:  C Johnson; L P Rome; T Stancin; M L Kumar
Journal:  Pediatrics       Date:  1989-09       Impact factor: 7.124

3.  Passive transfer of local immunity to influenza virus infection by IgA antibody.

Authors:  K B Renegar; P A Small
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

4.  Human cytotoxic T-cell memory: long-lived responses to vaccinia virus.

Authors:  W E Demkowicz; R A Littaua; J Wang; F A Ennis
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry.

Authors:  A B Sabin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

6.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers.

Authors:  R Cheynier; P Langlade-Demoyen; M R Marescot; S Blanche; G Blondin; S Wain-Hobson; C Griscelli; E Vilmer; F Plata
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

7.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

8.  Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine.

Authors:  B Brochier; M P Kieny; F Costy; P Coppens; B Bauduin; J P Lecocq; B Languet; G Chappuis; P Desmettre; K Afiademanyo
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

9.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

10.  T cell memory is short-lived in the absence of antigen.

Authors:  D Gray; P Matzinger
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  8 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness.

Authors:  G A D Hardy; N Imami; A K Sullivan; A Pires; C T Burton; M R Nelson; B G Gazzard; F M Gotch
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

4.  Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Authors:  P Polacino; V Stallard; J E Klaniecki; D C Montefiori; A J Langlois; B A Richardson; J Overbaugh; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Vaccination with attenuated simian immunodeficiency virus by DNA inoculation.

Authors:  S J Kent; C J Dale; S Preiss; J Mills; D Campagna; D F Purcell
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.

Authors:  P Polacino; V Stallard; D C Montefiori; C R Brown; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  Kunjin replicon-based simian immunodeficiency virus gag vaccines.

Authors:  Itaru Anraku; Vladislav V Mokhonov; Paweena Rattanasena; Ekaterina I Mokhonova; Jason Leung; Gorben Pijlman; Andrea Cara; Wayne A Schroder; Alexander A Khromykh; Andreas Suhrbier
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.